PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27442130-1	2017	PURPOSE: To evaluate the analgesic effect of bromfenac, a topically administered nonsteroidal antiinflammatory agent, in patients undergoing intravitreal injections (IVIs) of anti-vascular endothelial growth factor agents.	bromfenac	45-54	vascular endothelial growth factor A	Homo sapiens	180-214	
33727659-6	2021	Bromfenac also significantly decreased vascular endothelial growth factor level (P = 0.0077), as well as monocyte chemoattractant protein-1 level (P = 0.013), which was elevated for a prolonged period after phacoemulsification.	bromfenac	0-9	vascular endothelial growth factor A	Homo sapiens	39-73	
31534309-7	2019	Bromfenac was well tolerated when given alone or in combination with intravitreal anti-vascular endothelial growth factor agents, topical corticosteroids, or topical mast-cell stabilizers.	bromfenac	0-9	vascular endothelial growth factor A	Homo sapiens	87-121	
25006692-1	2014	BACKGROUND: According to recent studies, the newest strategy for the treatment of exudative age-related macular degeneration is to combine anti-VEGF agents with non-steroid anti-inflammatory drugs (NSAIDs) such as nepafenac and bromfenac to decrease the frequency of intravitreal injections.	bromfenac	228-237	vascular endothelial growth factor A	Homo sapiens	144-148